Clinical trials: Tumor Thrombus
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Cancer, Thrombus
The Impact of Climate Environment in Different Latitudes on the Occurrence of PICC Complications
In this study, eligible subjects were randomly assigned to the experimental or control group through randomization (1:1). Under the guidance of electrocardiographic Doppler ultrasound guided puncture and catheterization (EDUG)…
- Conditions
- Cancer, Thrombus, Phlebitis, Infections
- Trial name
- PICC (NCT05870449)
- Testing
- tunneled PICC, routine PICC
- Volunteers
- 1,666 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Head and Neck Cancer, Thromboembolism
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have…
- Trial name
- NCT00020189
- Testing
- acetylsalicylic acid, alvocidib, clopidogrel bisulfate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Terminal Cancer
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
Despite the fact that antithrombotic therapy (ATT) has little or even negative effects on the well-being of cancer patients during their last year of life, stopping ATT is rare in clinical practice.
- Trial name
- SERENITY (NCT05706740)
- Testing
- Physician survey on antithrombotic medication during end-of-life care in cancer patients
- Where
- 12 sites in Denmark, France and 6 more
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
Myeloproliferative Neoplasm
Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive.
- Trial name
- MPN-BIOCLOT (NCT04177576)
- Testing
- 2 additional tubes of blood
- Where
- 24 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Bordeaux
Venous Thromboembolism, Cancer
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism [VTE] in cancer patients at high risk for VTE and…
- Trial name
- SAVE-ONCO (NCT00694382)
- Testing
- Semuloparin sodium
- Where
- 411 sites in United States, Argentina and 47 more
- Volunteers
- 3,212 people
- Sponsor
- Sanofi
Venous Thromboembolism
Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism
This study is a multicenter post authorization observational study. Cancer patients diagnosed with non high risk VTE and are followed up in an outpatient setting will be treated with LMWH and the data will be recorded.
- Trial name
- TREBECA (NCT02017743)
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Trio Grup Clinical Research
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Venous Thrombosis
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
The treatment strategies for HCC with PVTT is still controversial, and differ substantially between the west and the east. According to western guidelines, including those of the EASL, BCLC, and AASLD, PVTT is regarded as a…
- Trial name
- TALENTOP (NCT04649489)
- Testing
- Atezolizumab & Bevacizumab, Surgery followed by atezolizumab and bevacizumab
- Where
- 23 sites in China
- Volunteers
- 501 people
- Sponsor
- Jia Fan
Venous Thromboses, Neoplasms
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
The purpose of this study is to identify risk factors of cancer-associated venous thrombosis and develop a prediction model to assist clinicians in tailoring anticoagulant therapy.
- Trial name
- NCT05729464
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Yongsheng Jiang
Cancer
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
- Trial name
- NCT00942968
- Testing
- dalteparin
- Where
- 42 sites in United States, Austria and 3 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Atrial Fibrillation, COVID-19
Positron Emission Tomography (PET) Imaging of Thrombosis
The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of…
- Conditions
- Atrial Fibrillation, COVID-19, Cancer, Thrombosis
- Trial name
- NCT03830320
- Testing
- [64Cu]FBP8, PET/MR, Blood Collection
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HCC - Hepatocellular Carcinoma
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with…
- Trial name
- NCT07776080
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Venous Thromboembolism, Cancer
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
- Trial name
- TRIM-Line (NCT05029063)
- Testing
- Rivaroxaban 10 MG
- Where
- 11 sites in Canada
- Volunteers
- 1,828 people
- Sponsor
- Ottawa Hospital Research Institute
Deep Vein Thrombosis
Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots
Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disorder after myocardial infarction and stroke.
- Trial name
- STEP-CAT (NCT02752607)
- Where
- 7 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Dr. Vicky Tagalakis
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi
The 1-year and 2-year overall survival rate (OS), local control rate (FFLP), disease-free progression time (PFS), and side effects were compared in patients with hepatocellular carcinoma limited to intrahepatic unresectable…
- Trial name
- NCT03939845
- Testing
- RT, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…
- Trial name
- NCT06492395
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Diffuse Large B Cell Lymphoma, Thrombosis
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Comparative Evaluation of Thrombotic Risk Models in DLBCL patients Objective: To assess the impact of thrombotic risk factors and compare the performance of existing predictive models (Khorana, Throly, Model IX) in Diffuse Large…
- Trial name
- PREDIC-TO (NCT06694779)
- Where
- Italy
- Volunteers
- 1,504 people
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo